Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05926102 · ClinicalTrials.gov registry record · NA
The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)
A NA study of Prostate Cancer, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- NA
- Development phase
- 5,000
- Enrollment target
- 1
- Study location
NCT05926102 is a NA study of Prostate Cancer that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 5,000 participants, above the 602-participant average among 735 other Prostate Cancer trials with a reported enrollment target (731% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05926102, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- NA
- Development phase
- 5,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and which men have significant prostate cancer needing treatment. False-positive screening tests can result in unnecessary prostate biopsies for men who do not need them. However, new genetic testing might help identify which men are at highest risk for prostate cancer. This study will examine whether a genetic test helps identify men at risk for significant prostate cancer while helping men who are at low risk for prostate cancer avoid unnecessary biopsies. If this genetic test proves beneficial, it will improve the way that healthcare providers screen male Veterans for prostate cancer.
Conditions Studied
Interventions
- OTHER Usual care
- GENETIC Precision screening intervention
Study Locations (1)
Massachusetts
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2030-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05926102
The ClinicalTrials.gov registry entry for NCT05926102 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 602-participant average among 735 other Prostate Cancer trials with a reported enrollment target (731% higher). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Usual care is the first listed.
NCT05926102 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05926102 about?
NCT05926102 is a clinical study titled "The Prostate Cancer, Genetic Risk, and Equitable Screening Study (ProGRESS)". Prostate cancer is the most common non-skin cancer among Veterans and the second leading cause of male cancer death. Current methods of screening men for prostate cancer are inaccurate and cannot identify which men do not have prostate cancer or have low-grade cases that will not cause harm and whic...
What is the current status of trial NCT05926102?
This trial is currently recruiting. It is a NA study. The enrollment target is 5,000 participants. The study started on 2024-02-01. Estimated completion is 2030-09-30.
What conditions does trial NCT05926102 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05926102?
The interventions under investigation include: Usual care (OTHER), Precision screening intervention (GENETIC).
Who is sponsoring clinical trial NCT05926102?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05926102 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.